Dolutegravir preferred option for HIV treatment: WHOJuly 23, 2019
The WHO has recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.
Initial studies had highlighted a possible link between DTG and neural tube defects such as spina bifida in infants born to women using the drug at the time of conception.
This potential safety concern was reported in May 2018 from a study in Botswana that found 4 cases of neural tube defects out of 426 women who became pregnant while taking DTG.
Based on these preliminary findings, many countries advised pregnant women and women of childbearing potential to take efavirenz (EFV) instead.
New data from two large clinical trials comparing the efficacy and safety of DTG and EFV in Africa have now expanded the evidence base. The risks of neural tube defects are significantly lower than what the initial studies may have suggested, wHO said in a statement.
The guidelines group also considered mathematical models of the benefits and harms associated with the two drugs; the values and preferences of people living with HIV, as well as factors related to implementation of HIV programmes in different countries, and cost.
DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used.
DTG also has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to EFV and nevirapine-based regimens.
In 2019, 12 out of 18 countries surveyed by WHO reported pre-treatment drug resistance levels exceeding the recommended threshold of 10%.
All of the above findings informed the decision to update the 2019 guidelines.
In 2019, 82 low-and middle-income countries reported to be transitioning to DTG-based HIV treatment regimens. The newly updated recommendations aim to help more countries improve their HIV policies.
The global agency on health also stresses the importance of providing information and options to help women make an informed choice while highlighting the need to continually monitor the risk of neural tube defects associated with DTG.